We are live on ! Find out more
BLRX

BioLineRX
BLRX

19 hedge funds and large institutions have $17.9M invested in BioLineRX in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

124% more capital invested

Capital invested by funds: $8.01M → $17.9M (+$9.92M)

58% more funds holding

Funds holding: 12 → 19 (+7)

Holders
19
Holders Change
+7
Holders Change %
+58.33%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$5.21M
2
SM
Senvest Management
New York
+$2.25M
3
BI
BVF Inc
California
+$2.19M
4
OM
Opaleye Management
Massachusetts
+$2.02M
5
SFM
Sphera Funds Management
Israel
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$85K
2
ARTA
A.R.T. Advisors
New York
-$28K
3
TRCT
Tower Research Capital (TRC)
New York
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$4.24M +$5.21M +3,171 New
SM
2
Senvest Management
New York
$3.46M +$2.25M +1,366 +112%
OM
3
Opaleye Management
Massachusetts
$3.24M +$2.02M +1,230 +104%
O
4
OrbiMed
New York
$2.53M – – –
BI
5
BVF Inc
California
$1.78M +$2.19M +1,333 New
SFM
6
Sphera Funds Management
Israel
$1.34M +$1.64M +1,000 New
Deutsche Bank
7
Deutsche Bank
Germany
$497K +$217K +132 +55%
PA
8
Perceptive Advisors
New York
$399K +$490K +298 New
Jane Street
9
Jane Street
New York
$130K +$161K +98 New
Citadel Advisors
10
Citadel Advisors
Florida
$72K +$88.8K +54 New
Renaissance Technologies
11
Renaissance Technologies
New York
$60K +$46K +28 +165%
BCA
12
Benchmark Capital Advisors
New York
$45K +$54.3K +33 New
VKH
13
Virtu KCG Holdings
New York
$41K +$14.8K +9 +41%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$40K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$27K – – –
Morgan Stanley
16
Morgan Stanley
New York
$21K +$26.3K +16 New
U
17
UBS
Switzerland
$7K +$8.22K +5 New
Wells Fargo
18
Wells Fargo
California
$2K – – –
Citigroup
19
Citigroup
New York
$2K +$1.64K +1 New
UBS AM
20
UBS AM
Illinois
– -$85K -50 Closed
ARTA
21
A.R.T. Advisors
New York
– -$28K -17 Closed
TRCT
22
Tower Research Capital (TRC)
New York
– -$28K -17 Closed

BLRX Hedge Fund Activity: Q1 2014 in Review

19 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2014, worth a combined $17.9M — up 124% from $8.01M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new BLRX positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $5.21M. The largest seller was UBS AM, exiting entirely with an estimated $85K sold.

  • 19 institutional investors held BioLineRX (BLRX) as of Q1 2014, up from 12 in Q4 2013.
  • Funds reported $17.9M of BioLineRX stock for Q1 2014, up 124% quarter-over-quarter.
  • 10 funds opened new BioLineRX positions in Q1 2014 and 3 closed out, a net change of +7 holders.
  • The largest BioLineRX buyer in Q1 2014 was Sabby Management, an estimated $5.21M added.
  • The largest BioLineRX seller in Q1 2014 was UBS AM, an estimated $85K sold.

Based on aggregated 13F filings for Q1 2014.